Drug Profile
OCV C02
Alternative Names: OCV-103/104; OCV-103/OCV-104; OCV-104/103; OCV-104/OCV-103; OCV-C02; OTS 103/104Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer OncoTherapy Science; Otsuka Pharmaceutical
- Class Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 17 Aug 2018 Discontinued - Phase-I for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in Japan (Parenteral) (Otsuka pipeline, August 2018)
- 20 Nov 2017 OCV C02 is still in phase I trials for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection) (Otsuka Pharmaceutical pipeline, November 2017)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection)